title: mTOR inhibitors in advanced renal cell carcinomas: from biology to clinical practice.
abstract: To date, oral everolimus is indicated for the treatment of patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with vascular endothelial growth factor-targeted therapy, and intravenous temsirolimus for the first-line treatment of patients with poor prognosis metastatic renal cell carcinoma. However, some factors could guide the treatment choice aiming to individualize a treatment plan. Besides the crucial issue of treatment efficacy, other factors are to be considered such as disease status, histological subtype, extent of the disease, patient-specific factors, and agent-specific factors. All of these considerations have to stay in the frame of guideline recommendations which represent evidence-based medicine. The purpose of this article is to summarize the main pharmacological and pharmacokinetic characteristics of mTOR inhibitors, and to define targeted populations according to prognostic indexes.
authors.affiliation: Department of Hematology and Oncology, Hôpital de Hautepierre, Avenue Molière, BP 49, 67098 Strasbourg Cedex, France. Electronic address: philippe.barthelemy@chru-strasbourg.fr.
authors.forename: Philippe
authors.initials: P
authors.lastname: Barthélémy
authors.forename: Benjamin
authors.initials: B
authors.lastname: Hoch
authors.forename: Christine
authors.initials: C
authors.lastname: Chevreau
authors.forename: Florence
authors.initials: F
authors.lastname: Joly
authors.forename: Brigitte
authors.initials: B
authors.lastname: Laguerre
authors.forename: François
authors.initials: F
authors.lastname: Lokiec
authors.forename: Brigitte
authors.initials: B
authors.lastname: Duclos
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D058990:Molecular Targeted Therapy; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D015398:Signal Transduction / Q000187:drug effects; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D058570:TOR Serine-Threonine Kinases
keywords: Everolimus; Kidney cancer; Temsirolimus; mTOR inhibitors